The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Donepezil for dementia with Lewy bodies: A randomized, placebo‐controlled trial
Open accessAbstract
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double‐blind, placebo‐controlled exploratory phase 2 trial. Methods: One‐hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, or 10mg of donepezil hydrochloride daily for 12 weeks (n = 35, 35, 33, and 37, respectively). Effects on cognitive function were assessed using the Mini‐Mental State Examination (MMSE) and several domain‐specific neuropsychological tests. Changes in behavior were evaluated using the Neuropsychiatric Inventory, caregiver burden using the Zarit Caregiver Burden Interview, and global function using the Clinician's Interview‐Based Impression of Change‐plus Caregiver Input (CIBIC‐plus). Safety measures included the Unified Parkinson's Disease Rating Scale part III. Results: Donepezil at 5 and 10mg/day was significantly superior to placebo on both the MMSE (5mg: mean difference, 3.8; 95% confidence interval [CI], 2.3–5.3; p < 0.001; 10 mg: mean difference, 2.4; 95% CI, 0.9–3.9; p = 0.001) and CIBIC‐plus (p < 0.001 for each); 3mg/day was significantly superior to placebo on CIBIC‐plus (p < 0.001), but not on the MMSE (p = 0.017). Significant improvements were found also in behavioral measures (p < 0.001) at 5 and 10mg/day and caregiver burden (p = 0.004) at 10 mg/day. The safety results were consistent with the known profile of donepezil and similar among groups. Interpretation: Donepezil at 5 and 10mg/day produces significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose. Donepezil is safe and well tolerated. ANN NEUROL 2012;72:41–52
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · cited 2×
“NPI-plus is a 12-item version of the NPI, with the original 10 items supplemented by 2 DLB-relevant domains of sleep and cognitive fluctuation.(11,20,21) Patients had caregivers who routinely stayed with them at least 3 days per week and 4 hours per day, provided information for this study, assisted compliance with tr…”
MethodRelatives of the Impaired Elderly: Correlates of Feelings of Burden
Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980) · The Gerontologist · doi:10.1093/geront/20.6.649 · Cited by 5,810
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · cited 1×
“The core clinical features of DLB include neuropsychiatric symptoms and motor symptoms of parkinsonism as well as cognitive impairment characterized by deficits of attention, executive function, and visual perception.(2) Fluctuating cognition, hallucinations, and delusions are major sources of difficulties and distres…”
BackgroundSelf-citationWechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Understanding Psychological Assessment · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,731
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients
Cummings, J. L. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.10s · Cited by 2,017
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00462-6 · Cited by 592
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
New evidence on the management of Lewy body dementia
Taylor, J.-P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., Allan, L. M., Thomas, A. J., & O'Brien, J. T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30153-x · Cited by 347
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Wang, H.-F., Yu, J.-T., Tang, S.-W., Jiang, T., Tan, C.-C., Meng, X.-F., Wang, C., Tan, M.-S., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307659 · Cited by 269
Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis
Stinton, C., McKeith, I., Taylor, J.-P., Lafortune, L., Mioshi, E., Mak, E., Cambridge, V., Mason, J., Thomas, A., & O’Brien, J. T. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121582 · Cited by 264
Kazui, H., Yoshiyama, K., Kanemoto, H., Suzuki, Y., Sato, S., Hashimoto, M., Ikeda, M., Tanaka, H., Hatada, Y., Matsushita, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161092 · Cited by 160
Self-citationd’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Dementia with Lewy bodies: Challenges in the diagnosis and management
Chin, K. S., Teodorczuk, A., & Watson, R. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835029 · Cited by 63
Shimada, H., Hirano, S., Sinotoh, H., Ota, T., Tanaka, N., Sato, K., Yamada, M., Fukushi, K., Irie, T., Zhang, M. R., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4338 · Cited by 40
“Moreover, acetylcholinesterase inhibitors are widely used for symptomatic therapy in AD patients, and they are also effective against cognitive decline and associated psychiatric symptoms such as attention deficit and visual hallucination observed in DLB (Mori et al., 2012).”
BackgroundChu, C.-S., Yang, F.-C., Tseng, P.-T., Stubbs, B., Dag, A., Carvalho, A. F., Thompson, T., Tu, Y.-K., Yeh, T.-C., Li, D.-J., et al. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104474 · Cited by 14
Self-citationSugawara Kikuchi, Y., & Shimizu, T. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189050 · Cited by 14
Suzuki, Y., Suzuki, M., Shigenobu, K., Shinosaki, K., Aoki, Y., Kikuchi, H., Baba, T., Hashimoto, M., Araki, T., Johnsen, K., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0265484 · Cited by 10
Self-citation
Metadata
- Authors
- Mori, E., Ikeda, M., Kosaka, K., & on behalf of the Donepezil‐DLB Study Investigators
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-07
- Volume
- 72
- Issue
- 1
- Pages
- 41-52
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2010076518
- Cited by
- 274
- References
- 36
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.